Teva has announced the temporary suspension of marketing, distribution and sales of its Zecuity patch in the U.S. to investigate the cause of burns and scars related to its use.
The company voluntarily suspended sales of the migraine patch based on a flood of post-marketing reports dating from September 2015, linking the patch to adverse application site reactions including burns, scars, cracked skin and discoloration ().
FDA and Teva will work in partnership to determine the cause of the adverse events. Until an investigation is completed, the company is recalling all patches at the pharmacy-level and putting further sales on hold.
Teva gained rights to Zecuity along with its acquisition of NuPathe in January 2014. — Joya Patel